Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 826 participants.

Also called NCT02983214

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose health services research
Phase
Phase 4
Enrolled
  • 826 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02983214
Other papers using this trial's data
  • Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events Journal of the American Heart Association, 2021-01-05 DOI, PubMed 33327737, PMC7955466 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Greece (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02983214. Randomized; no masking; primary purpose health services research. Start 2016-11 (actual); primary completion 2019-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
Acronym
DORIC
Condition
Peripheral Artery Disease
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Cilostazol
Lead sponsor
University of Ioannina (class: other)
Collaborator
LIBYTEC Pharmaceutical S.A. (class: not stated)

Record details

Record id
cardio:ct-nct02983214
Content hash
4189cd70a0c78927a4fec37ba9223639062b35388d9ea1a5dece9f5509311c93